01Feb 2023
Adjuvant Immunotherapy in Renal Cell Carcinoma: A Systematic Review and Meta‐Analysis

Adjuvant Immunotherapy in Renal Cell Carcinoma: A Systematic Review and Meta‐Analysis

The review article aimed to synthesize available data regarding the disease‐free survival (DFS) benefit of adjuvant immune checkpoint inhibitors (ICIs) for patients with RCC and evaluate the overall safety profile of ICIs in this setting. Among the four included studies, one demonstrated a significant DFS benefit. However, there was considerable clinical and statistical heterogeneity (I2=64%) due to differences in inclusion criteria and interventions. While pooled results across the four studies did not demonstrate a significant benefit in DFS overall (HR 0.85, 95% CI 0.69‐1.04), there was a significant benefit among patients with positive PD‐L1 expression and sarcomatoid features. The evidence base to date regarding ICI as adjuvant therapy in RCC is mixed – conclusions are limited by considerable heterogeneity between studies. However, pooled analyses suggest that patients with positive PD‐L1 expression or sarcomatoid features are most likely to benefit from adjuvant immunotherapy.

  • #urology

Like

Save

Share